Clinical trials: Idarubicin
Acute Myeloid Leukemia
Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
This trial is a study on all-trans retinoic acid in combination with induction and consolidation therapy as well as pegfilgrastim after consolidation therapy in younger patients with newly diagnosed acute myeloid leukemia (AML).
- Trial name
- NCT00151242
- Testing
- Cytarabine, Idarubicin, Etoposide
- Where
- 34 sites in Austria, Germany
- Volunteers
- 920 people
- Sponsor
- University of Ulm
Multiple Myeloma
Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma
Background: In some studies, thalidomide in combination with chemotherapy has been shown to be effective in patients with relapsed or refractory multiple myeloma (MM).
- Trial name
- NCT00124813
- Testing
- thalidomide, idarubicin
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- University Hospital, Bonn
Leukemia, Myelodysplastic Syndromes
Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia
RATIONALE: Drugs used in chemotherapy, such as clofarabine, cytarabine, and idarubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- AML-14A (NCT00838240)
- Testing
- clofarabine, cytarabine, idarubicin
- Where
- 10 sites in Belgium, Croatia and 3 more
- Volunteers
- 114 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Combination Chemotherapy in Treating Patients With Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00002835
- Testing
- Bleomycin Sulfate (BLM), Filgrastim (G-CSF), Recombinant Interferon Alfa
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- M.D. Anderson Cancer Center
FLT3-mutated Acute Myeloid Leukemia
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
This study will evaluate the safety, efficacy and pharmacokinetics of midostaurin in combination with standard chemotherapy in pediatrics patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia.
- Trial name
- NCT03591510
- Testing
- Midostaurin, Fludarabine, Cytarabine
- Where
- 15 sites in Czechia, Germany and 8 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Primary Central Nervous System Lymphoma
Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.
- Trial name
- NCT02657785
- Testing
- R-IDARAM plus intrathecal chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Navy General Hospital, Beijing
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for multiple myeloma.
- Trial name
- NCT00006232
- Testing
- dexamethasone, doxorubicin hydrochloride, idarubicin
- Where
- 12 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- West of Scotland Lymphoma Group
Myeloid Leukemia
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
The goal of Phase 1b is to establish the safety of asciminib in combination with FLAG-Ida and venetoclax in patients with CML-MBP, CML-LBP, and Ph+ AML.
- Trial name
- NCT07604233
- Testing
- Fludarabine, Cytarabine, Idarubicin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
MRD Response-adapted Allo-HSCT for Adverse-risk AML
This TROPHY-AML01 regimen aims to identify the effectiveness and safety of MRD response-adapted allo-HSCT for adverse-risk acute myeloid leukemia in an open-label, randomized, controlled trial.
- Trial name
- NCT06301425
- Testing
- Intervention group, Control group
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Peking University People's Hospital
Acute Myeloid Leukemia
Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients
Whether Idarubicin can overcomes multidrug resistant 1 induced chemoresistance with higher induction remission rate than daunorubicin in de novo acute myeloid leukemia patients.Whether induction therapy with IA regimen has a…
- Trial name
- NCT01889407
- Testing
- Idarubicin
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Cancer, Metastatic Cancer
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Trans arterial chemoembolization (TACE) has emerged as a treatment option for chemotherapy-refractory diseases in Liver metastases.
- Conditions
- Cancer, Metastatic Cancer, Liver Metastases
- Trial name
- NCT06311851
- Testing
- Bevacizumab
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Pardis Noor Medical Imaging and Cancer Center
B Acute Lymphoblastic Leukemia
Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL
Blinatumomab, a CD3/CD19 bisespecific T-cell conjugative antibody, has shown high efficacy in phase I/II studies of relapsed/refractory B-lymphoblastic leukemia (B-ALL), particularly in the context of low tumor burden.Meanwhile…
- Trial name
- NCT05557110
- Testing
- Blinatumomab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Chen Suning
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS
Reduced intensive 3 + 5 idarubicin and cytarabine chemotherapy plus venetoclax as first-line treatment for adults with acute myeloid leukaemia and high-risk myelodysplastic syndrome
- Trial name
- NCT06050941
- Testing
- idarubicin, Cytarabine
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Liver Cancer, Antibody
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
This trial is designed to investigate the safety, response rates and survival outcomes of patients with hepatocellular carcinoma by infusion of CTLA4, PD1 and PDL1 antibodies combination with chemodrug or/and bevacizumab through…
- Trial name
- NCT06482801
- Testing
- ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Leukemia
Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003729
- Testing
- cytarabine, fludarabine phosphate, idarubicin
- Where
- 23 sites in Belgium, France and 1 more
- Volunteers
- 13 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Leukemia
LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The goal of this clinical research study is to learn about the safety of LY2510924 in combination with cytarabine and idarubicin in patients with relapsed or refractory AML.
- Trial name
- NCT02652871
- Testing
- LY2510924, Idarubicin, Cytarabine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia, Adult
Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL
This study aims to evaluate an integrated treatment protocol for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL), combining induction chemotherapy, consolidation therapy, and allogeneic…
- Trial name
- NCT07059156
- Testing
- Induction Therapy Regimen, Pre-Treatment Regimen, Post-CR Treatment
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanxi Bethune Hospital
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Adoptive Transfer of Haplo-identical DLI for AML and MDS
The primary hypothesis is that chemotherapy followed by donor lymphocyte infusion (DLI) from HLA-haploidentical donors is a safe procedure that will not cause Graft versus Host Disease (GVHD) or increased treatment-related…
- Trial name
- NCT02046122
- Testing
- Idarubicin, Cytarabine, DLI
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Duke University
Primary Central Nervous System Lymphoma
Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma
Idarubicin combined with high dose methotrexate and moderate dose radiotherapy will achieve similar survival outcomes but with reduced neurotoxicity compared to regimens using methotrexate with high dose radiotherapy.
- Trial name
- NCT00193973
- Testing
- Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C, Radiation Therapy
- Where
- 15 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Acute Myeloid Leukemia (AML)
"InDACtion" vs "3+7" Induction in AML
Older patients with acute myeloid leukemia (AML) have a small (< 10%) chance of long-term survival. Despite the treatment of elderly AML patients with intensive chemotherapy, the survival has not been improved during the last…
- Trial name
- NCT02172872
- Testing
- standard combination chemotherapy, decitabine
- Where
- 53 sites in Belgium, Bulgaria and 7 more
- Volunteers
- 606 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC